February 22, 2018 / 12:00 PM / 3 months ago

BRIEF-Sage Therapeutics Qtrly Net Loss Per Share $1.75

Feb 22 (Reuters) - Sage Therapeutics Inc:

* SAGE THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE

* ON TRACK TO SUBMIT NEW DRUG APPLICATION FOR BREXANOLONE FOR POSTPARTUM DEPRESSION IN 1H 2018 FOLLOWING PRE-NDA MEETING

* ON TRACK TO SUBMIT NEW DRUG APPLICATION FOR BREXANOLONE FOR POSTPARTUM DEPRESSION IN 1H 2018 FOLLOWING PRE-NDA MEETING

* QTRLY NET LOSS PER SHARE - BASIC AND DILUTED $1.75

* CASH, CASH EQUIVALENTS,MARKETABLE SECURITIES AS OF DEC 31, 2017 WERE $518.8 MILLION, VERSUS $397.5 MILLION AT DECEMBER 31, 2016

* EXPECTS OPERATING EXPENSES TO INCREASE YEAR OVER YEAR IN 2018

* Q4 EARNINGS PER SHARE VIEW $-1.99 — THOMSON REUTERS I/B/E/S

* SAGE -EXPECTS EXISTING CASH,CASH EQUIVALENTS, MARKETABLE SECURITIES, OTHER SALES TO ENABLE CO TO FUND OPERATING EXPENSES, CAPEX REQUIREMENTS INTO 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below